Financial Results for the quarter and year ended 31st March, 2026

Emphasis of matterRevenue declinedNet loss reportedEBITDA margin compressionExceptional itemResults restatedResults View source PDF Explain this filing

AKUMS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.5%Reaction day

₹540.00

prior close

₹520.00

announcement price

In-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+0.2%-1.8% vs market

Pharmaceuticals peers, median of 161sector+0.4%-1.9% vs sector

On the reaction day the stock moved 1.8 pts less than Nifty Microcap 250 and 1.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.9

10m

+3.5

15m

+2.8

30m

+1.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.5+0.2-1.8+0.4-1.9

Next day

-4.3-0.1-4.2+0.1-4.4

-4.8-1.5-3.3-0.4-4.4

-3.7-1.0-2.7+0.0-3.8

-5.1-0.4-4.6+1.2-6.3

-3.1+0.6-3.7+2.1-5.1

-3.5+2.3-5.8+1.1-4.6

15d

+2.4+3.5-1.1+1.4+1.0

+14.6+5.6+9.1+2.2+12.4

+27.2+9.5+17.7+7.9+19.3

+34.2+13.3+21.0+8.1+26.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 161Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Akums Drugs and Pharmaceuticals reported standalone revenue from operations of Rs 13,487.36 million for FY2026, a modest increase of about 2.8% from Rs 13,117.84 million in FY2025. However, profit after tax declined significantly by 30.7% to Rs 1,116.40 million from Rs 1,609.98 million, indicating margin compression despite stable revenue growth. The company recognized exceptional items of Rs 65.19 million for the year, comprising Rs 52.32 million for impact of new labour codes and Rs 12.87 million for retrospective VDA arrears. The board recommended a final dividend of Rs 1 per share plus a special dividend of Rs 2 per share. The statutory auditor Walker Chandiok & Co. LLP issued an unmodified opinion but included an Emphasis of Matter paragraph regarding an Income Tax Department search and seizure operation conducted in January 2025 and subsequent show cause notices received in May 2026, where the impact remains not ascertainable. Current borrowings increased sharply from Rs 39.30 million to Rs 1,355.2 million.

Likely market impact

The 30.7% decline in profit despite marginal revenue growth signals operational margin pressure. The unresolved Income Tax search proceedings and show cause notices represent a regulatory risk factor. Higher borrowing levels also indicate increased financial leverage.